)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
COSMOS Pharmaceutical
COSMOS Pharmaceutical (3349) investor relations material
COSMOS Pharmaceutical Q1 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2027 earnings summary13 Oct, 2026
Executive summary
Q1 FY2027 net sales rose 5.2% YoY to ¥286,653 million; operating profit rose 3.1% to ¥12,005 million and profit attributable to owners of parent rose 1.0% to ¥8,251 million.
Store expansion and low-cost operations supported results amid inflation, yen weakness and Middle East-related oil supply concerns.
Financial highlights
Gross profit increased to ¥62,129 million from ¥57,174 million; SG&A rose to ¥50,124 million from ¥45,529 million.
EBITDA was ¥17,911 million, up 5.7% YoY; ordinary profit was ¥12,766 million, up 4.7%.
Extraordinary losses totaled ¥407 million, including ¥204 million from disaster losses and ¥91 million from store closings.
Outlook and guidance
FY2027 guidance remains unchanged: net sales ¥1,190,000 million (+8.2%), operating profit ¥43,000 million (+1.5%), ordinary profit ¥45,700 million (+2.4%) and parent profit ¥30,700 million (-4.2%).
H1 guidance: net sales ¥582,700 million (+8.5%), operating profit ¥20,780 million (+0.5%), ordinary profit ¥22,180 million (+1.1%) and parent profit ¥14,480 million (-1.2%).
FY2027 forecast EPS is ¥387.35; H1 forecast EPS is ¥182.70. Forecasts are subject to risks and assumptions, and actual results may differ significantly.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from COSMOS Pharmaceutical
- Sales and profits rose on store growth, with FY2027 guidance for higher sales and dividends.3349
Q4 2026 - Net sales rose 7.7% and profit attributable to owners increased 1.8% year-over-year.3349Q3 2026
- Strong sales and profit growth achieved through expansion and operational efficiency.3349Q2 2025
- Sales and profits rose modestly, with strong store expansion and stable financial outlook.3349Q2 2026
- Strong sales and profit growth, with continued expansion and a 2-for-1 stock split planned.3349Q4 2024
- Strong sales and profit growth achieved despite economic headwinds, with positive full-year outlook.3349Q1 2025
- Strong profit growth and store expansion achieved amid economic headwinds and rising costs.3349Q3 2025
- Strong profit growth and continued store expansion drive positive outlook and higher dividends.3349Q4 2025
- Net sales rose 4.0% and operating profit edged up 0.6% year-over-year, with 12 new stores opened.3349Q1 2026
Next COSMOS Pharmaceutical earnings date
Q2 202712 Jan, 2027
COSMOS Pharmaceutical
Next COSMOS Pharmaceutical earnings date
Q2 202712 Jan, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)